Journal of International Oncology››2014,Vol. 41››Issue (8): 574-576.doi:10.3760/cma.j.issn.1673-422X.2014.08.005
Previous ArticlesNext Articles
Huang Cheng, Ma Xiaoli
Received:2014-02-24Revised:2014-04-04Online:2014-08-15Published:2014-08-14Contact:Ma Xiaoli E-mail:mxl1123@sina.comHuang Cheng, Ma Xiaoli. Influence factors of vincristine′s adverse reaction[J]. Journal of International Oncology, 2014, 41(8): 574-576.
| ［1］ Silverman JA, Deitcher SR. Marqibo (vincristine sulfate liposome injection) improves the pharmacokinetics and pharmacodynamics of vincristine［J］. Cancer Chemother Pharmacol, 2013, 71(3): 555-564. ［2］ Dennison JB, Jones DR, Renbarger JL, et al. Effect of CYP3A5 expression on vincristine metabolism with human liver microsomes［J］. J Pharmacol Exp Ther, 2007, 321(2): 553-563. ［3］ Dennison JB, Mohutsky MA, Barbuch RJ, et al. Apparent high CYP3A5 expression is required for significant metabolism of vincristine by human cryopreserved hepatocytes［J］. J Pharmacol Exp Ther, 2008, 327(1): 248-257. ［4］ van Schaik RH. CYP450 pharmacogenetics for personalizing cancer therapy［J］. Drug Resistance Updates, 2008, 11(3): 77-98. ［5］ Lange BJ, Bostrom BC, Cherlow JM, et al. Doubledelayedintensi fication improves eventfree survival for children with intermediaterisk acute lymphoblastic leukemia: a report from the Children′s Cancer Group［J］. Blood, 2002, 99(3): 825-833. ［6］ Egbelakin A, Ferguson MJ, MacGill EA, Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemia［J］. Pediatr Blood Cancer, 2011, 56(3): 361-367. ［7］ Brūggemann RJ, Alffenaar JW, Blijlevens NM, et al. Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents［J］. Clin Infect Dis, 2009, 48(10): 1441-1458. ［8］ 冷玲, 佟仲生. 常用化疗药物的脂质体剂型［J］. 国际肿瘤学杂志, 2008, 35(8): 585-587. ［9］ 李文静, 杨志强, 王杏林. 硫酸长春新碱脂质体研究进展［J］. 中国新药杂志, 2012, 21(13): 1479-1484. |
| [1] | Yang Hao, Shi Guidong, Zhang Chengcheng, Zhang Yue, Zhang Liwen, Fu Maoyong.Comparison of efficacy and safety between sintilimab and tislelizumab in neoadjuvant therapy for advanced esophageal squamous cell carcinoma[J]. Journal of International Oncology, 2024, 51(4): 210-216. |
| [2] | Yan Aiting, Wang Cuizhu, Liu Chungui, Lu Xiaomin.Clinical efficacy and safety of camrelizumab and sintilimab in the treatment of advanced non-small cell lung cancer[J]. Journal of International Oncology, 2024, 51(3): 137-142. |
| [3] | Deng Juanjun, Zhao Dayong, Li Miao.Adverse reactions and risk factors of immune checkpoint inhibitors in the treatment of non-small cell lung cancer[J]. Journal of International Oncology, 2023, 50(9): 564-568. |
| [4] | Yuan Xiaobin, Wang Yang, Yang Min, Wu Pengxiang, Shen Zhilin, Ma Yongbin, Ding Lieming.Analyzing and monitoring real-world clinical safety of ensartinib for the treatment of patients with ALK-positive non-small cell lung cancer[J]. Journal of International Oncology, 2023, 50(3): 150-156. |
| [5] | Zhou Ting, Xu Shaohua, Mei Lin.Efficacy and safety of bevacizumab combined with capecitabine in the treatment of advanced breast cancer[J]. Journal of International Oncology, 2023, 50(3): 144-149. |
| [6] | Jiao Panpan, Xue Lijuan, Zhan Juan.Risk factors and predictors of immune-related adverse events induced by immune checkpoint inhibitors[J]. Journal of International Oncology, 2023, 50(12): 739-744. |
| [7] | Pang Jingdan, Du Yingying, Da Jie.Adverse reactions and treatment measures of advanced solid tumors treated with antibody-drug conjugates[J]. Journal of International Oncology, 2022, 49(4): 220-224. |
| [8] | Lin Rongsheng, Wu Chuhai, Guo Yingmei, Wang Tao, Chen Rongbin, Liu Shaoqin, Gan Bing.Efficacy and safety of teriprizumab combined with bevacizumab in the treatment of metastatic MSI-H colorectal cancer above the second line[J]. Journal of International Oncology, 2022, 49(2): 100-105. |
| [9] | Zhou Liya, Li Xiaoli, Cao Zixiao, Xiang Junxin, Liu Jiahui, Xia Xuemei, Li Dianming.Clinical observation of albumin-bound paclitaxel or pemetrexed combined with cisplatin in the treatment of advanced mutation negative lung adenocarcinoma[J]. Journal of International Oncology, 2021, 48(10): 596-601. |
| [10] | Gao Shile, Lu Donghui, Liu Meiqin, Xu Xingjun, Xu Mingjing, Ma Huan.Clinical efficacy and safety evaluation of apatinib combined with tegio in the treatment of advanced esophageal cancer[J]. Journal of International Oncology, 2020, 47(12): 716-722. |
| [11] | Jiang Zhouna1, Zhang Jie1, Shen Qianqian1, Zhang Fang2, Lyu Wei2, Zheng Yawen2.Analysis of clinical efficacy and prognostic factors of apatinib in the treatment of advanced malignant tumors[J]. Journal of International Oncology, 2019, 46(5): 272-277. |
| [12] | Yang Chunhua, Wang Xia, Zhang Longzhen, Chen Jie, Tang Tianyou, Liu Guihong.Clinical study on simultaneous modulated accelerated radiotherapy for advanced cervical cancer[J]. Journal of International Oncology, 2018, 45(8): 544-547. |
| [13] | ZHANG Xiao-Fei, WEI Ya-Qiang.Effect of different chemotherapy combined with radiotherapy for the treatment of nonsmall cell lung cancer complicated with type 2 diabetes[J]. Journal of International Oncology, 2017, 44(2): 95-98. |
| [14] | Wang Liang, Wu Changhua, Zou Shujuan, Chen Wanjun.Influencing factors of lateral lymph node metastasis in papillary thyroid carcinoma[J]. Journal of International Oncology, 2016, 43(3): 207-209. |
| [15] | ZHANG Yi-Fan, YIN Hai-Tao .Biomarkers of colorectal cancer in individual therapy[J]. Journal of International Oncology, 2015, 42(8): 710-. |
| Viewed | ||||||
| Full text |
|
|||||
| Abstract |
|
|||||
